A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic)

Titre officiel

A Phase I/Ib Global, Multicentre, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Sommaire:

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumours are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Description de l'essai

Primary Outcome:

• Objective Response Rate

• Duration of Response
• Disease Control Rate
• Percentage of Participants with Adverse Events (AEs)

Voir cet essai sur ClinicalTrials.gov